Gilead: latest news - GoINPHARMA
Tuesday, 22 January 2019 - 3:37

Gilead

Gilead turns the page

US-based biotech Gilead Sciences has announced that it has appointed veteran Daniel O’Day as next CEO. O’Day, 54, was born in the US and has been working for Roche for 30 years, in three different continents and in positions requiring…

Gilead reports new data on efficacy of CAR-T therapy Yescarta

Gilead has reported results from ZUMA-1 clinical trial, designed to assess the breakthrough investigational therapy Yescarta (axicabtagene ciloleucel), on patients with large B-cell lymphoma. The treatment has been developed by Kite, the biotech acquired by Gilead in 2017. The trial…

Gilead can now attempt at takeover of Galapagos

The Dutch economic and financial daily Het Financieele Dagblad today has reviewed the press release issued by Belgian-Dutch biotech company Galapagos to announce that Van Herk Investments’ stake in the company has decreased to 9.91% due to dilution. As a…

Renewed talk about Gilead seeking to acquire Tesaro ($2bn)

Bloomberg has reported that Tesaro is seeking a sale, which was enough for its shares to be up over 30% as trading closed last Friday. According to the report, some potential acquirers have already stepped up, and the company’s management…

Gilead and Intercept draw closer to launch new NASH therapies

The most debated issue at Liver Meeting, organized by AASLD (American Association for Study of Liver Diseases) and underway in San Francisco in these days, are probably therapies for non-alcoholic steatohepatitis. Four companies already have NASH therapies undergoing clinical trials–Intercept…

Galapagos CEO says a sale to Gilead is 50% likely

The daily De Telegraaf on Saturday published a statement by Onno van De Stolpe, CEO of Belgium-based biotech Galapagos, according to which the group is 50% likely to be acquired by a competitor over the next 10 years.  The chief…

At last, positive quarter for Gilead

Gilead’s third quarter has been the first to show recovery signs from California-based biotech giant. The division selling products for hepatitis C treatment lost revenues in favor of competitors again (-14%). By sharp contrast, sales from HIV and antivirals divisions…

Gilead makes brave decision: announces launch of generics to Harvoni and Epclusa

Gilead Sciences has announced it has created the subsidiary Asegua Therapeutics LLC, a company that will distribute generics–specifically  Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg). The two drugs are the group’s blockbusters for hepatitis C, and their sales…

Galapagos opposes takeover attempt by Gilead

Onno van de Stolpe, CEO of Belgium-based biotech Galapagos, has reported to Belgian daily De Tijd that his company won’t be acquired in the near future by US-based Gilead and will, instead,  remain independent. The statement addresses the rumors circulating…

Excellent Phase III results for Gilead-Galapagos’ Filgotinib

Gilead announced yesterday, after trading had closed, that its investigational therapy Filgotinib (JAK-1 inhibitor), developed and licensed by Belgian biotech Galapagos, has reached all its primary and secondary endpoints in the early stages of the Phase III clinical trial Fitch-2….

Gilead’s Yescarta (CAR-T) obtains marketing approval in Europe

Gilead announced today, before trading started in Wall Street, that the European Commission has granted marketing approval to Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with DLBCL (diffuse large B cell lymphoma) and PMBCL (primary mediastinal B-cell lymphoma)….

Gilead sells investigational therapy momelotinib to Sierra Oncology for $198m

Canada-based biotech Sierra Oncology has announced it has acquired momelotinib, an investigational therapy for the treatment of myelofibrosis developed by California-based Gilead Sciences. The deal includes an upfront $3m payment by Sierra, plus additional  payments based on successful completion of…

New disappointing quarter from Gilead, CEO announces resignation

Another disappointing quarter from biotech Gilead – its shares have lost 2.4% in after-market trading as investors have lost patience and interest in the company’s shares. In addition to announcing the results, CEO John Milligan has announced he will leave…

Gilead keeps investing on cancer sector

Gilead has announced today to the financial community that it has signed an agreement with Netherlands-based Gadeta to develop a new range of TCR immunotherapies for the treatment of solid and blood cancer types. Thanks to the agreement, Gilead will…

The state of pharmaceutical industry in the US

The US pharma sector is delivering positive results if the main indicators are considered – for instance, health-care spending has reached 18% of the country’s GDP now, and it is estimated to grow by 68% to $600bn before 2026. Despite…

NASH sector heats up

Bloomberg yesterday reported that biotech Madrigal Pharmaceuticals  is weighing a sale after some early talks with large pharmaceutical groups. The news has made Madrigal’s shares jump by over 150% in the last month. Madrigal is a biotech based in Pennsylvania,…

Gilead-Galapagos’ Filgotinib shows efficacy in treating psoriatic arthritis

Gilead Sciences and Belgium-based biotech Galapagos yesterday announced, after Wall Street closed, data from the Phase II EQUATOR trial assessing filgotinib on 131 patients with psoriatic arthritis. The results are positive and demonstrate that filgotinib improves patients’ conditions after as…

Neue Entwicklungen der Membrantechnologie zur Wasserentsalzung

Ein Forscherteam der Zhejiang University von Hangzhou in China hat in der berühmten Zeitschrift Science die Synthese neuer Nanomembranen für die Wasserentsalzung gezeigt. Die neue Membran hat eine Struktur, die eine bessere Separierung großer Ionen ermöglicht und wird durch die…

Another disappointing quarter from Gilead, shares down almost 6%

Gilead has posted another disappointing quarter and its shares have reacted by dropping 5.8% in after-hours trading.  The cause for the decline has been the same for two years now–sales of hepatitis C drugs keep dropping, since the disease is…

Gilead surprises markets again: signed $3bn agreement with Sangamo

Gilead surprised markets again today as it announced, before Wall Street opened, it has entered into an agreement with Sangamo Therapeutics. The deal grants the California-based company access to Sangamo’s “zinc finger nuclease” technology platform for the development of novel…

Gilead wins appeal against Merck & Co. and saves $2.54bn

A judge in the federal court in Delaware has ruled in favor of Gilead in an appeal trial concerning patent issues against Merck & Co.. Specifically, the judge has held invalid Merck & Co.’s patent protecting a hepatitis C treatment,…

Galapagos tries to avoid being acquired by Gilead

The Dutch economic and financial daily Het Financieele Dagblad has published today a front-page article reporting that Belgium-based biotech Galapagos is looking for an important shareholder protecting it from Gilead. Gilead already owns 13% of the company. Galapagos CEO Van…